Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ASPIRE: DETERIMINING THE IMPACT OF CRISABOROLE (Eucrisa) AND TACROLIMUS 0.03% ON PATIENT-REPORTED OUTCOMES AND CAREGIVER BURDEN IN CHILDREN WITH ATOPIC DERMATITIS

Trial Profile

ASPIRE: DETERIMINING THE IMPACT OF CRISABOROLE (Eucrisa) AND TACROLIMUS 0.03% ON PATIENT-REPORTED OUTCOMES AND CAREGIVER BURDEN IN CHILDREN WITH ATOPIC DERMATITIS

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Jan 2019

At a glance

  • Drugs Crisaborole (Primary) ; Tacrolimus
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Acronyms ASPIRE
  • Most Recent Events

    • 22 Jan 2019 Planned End Date changed from 31 Aug 2020 to 30 Sep 2020.
    • 22 Jan 2019 Planned primary completion date changed from 30 Apr 2020 to 30 Jun 2020.
    • 22 Jan 2019 Planned initiation date changed from 1 Oct 2018 to 4 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top